TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

Abbott’s new self-expanding TAVR system gains CE mark approval

The solution has still only been approved in the United States for investigational use. 

BASILICIA before TAVR is safe and effective, new data confirms

Researchers found that the procedure was associated with a high success rate and low mortality and stroke rates after 30 days.

Thumbnail

AI model helps clinicians predict post-TAVR infective endocarditis

To build and validate their advanced AI model, researchers explored data from nearly 78,000 TAVR hospitalizations.

quality imaging appropriateness clinical decision support CAS AUC

11% of TAVR sites deliver below-average care, suggesting a ‘meaningful performance gap’

The study’s authors developed and validated a new performance measure for TAVR care using data from more than 52,000 patients. They shared their full analysis ahead of print in Circulation.

Thumbnail

1 in 10 patients with post-TAVR infective endocarditis have a stroke, increasing risk of death by 90%

When patients with post-TAVR infective endocarditis have a stroke, their risk of in-hospital mortality and all-cause mortality after one year both skyrocket. 

How valve type and anesthesia strategy affect 1-year TAVR outcomes

Researchers in Germany explored data from more than 400 TAVR patients, sharing their findings in the Journal of the American College of Cardiology. 

Thumbnail

Risk of a permanent pacemaker after valve-in-valve TAVR is low, especially when using newer heart valves

The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.

Displaying 345 - 352 of 401
Design by Adaptive Theme